Biphenylmethane Thyromimetics for Selective TRβ Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for thyroid-related diseases lack effective, selective thyroid hormone receptor-beta (TRβ) modulators that can address conditions such as non-alcoholic fatty liver disease (NAFLD), hepatocellular carcinoma (HCC), and neurodegenerative diseases like multiple sclerosis, Alzheimer's, and Parkinson's without the severe adverse effects associated with thyroid hormones.
Innovation Solution
Development of novel small molecules, specifically compounds of Formula (I), which act as selective TRβ modulators, inducing hepatomitogenic effects and activating AMPK, thereby promoting lipolysis and treating the mentioned diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thyroid hormones (THs) are used for pharmacological treatment, then metabolic homeostasis and liver disease treatment effects are improved, but severe adverse side effects (increased heart rate, cardiac hypertrophy, muscle wasting, reduced bone density) occur
Solution Approach 1:
The invention segments the thyroid hormone receptor system into two distinct targets: TRα and TRβ. By designing compounds that selectively modulate only TRβ, the patent isolates the therapeutic effects (liver disease treatment, metabolic regulation) from the adverse effects (cardiac and bone side effects) that are mediated through TRα activation.
Solution Approach 2:
The patent applies local quality by creating compounds with differential affinity for different receptor isoforms. The selective TRβ modulators exhibit high specificity for TRβ while showing minimal or no activity at TRα, thereby producing localized therapeutic effects in liver and metabolic tissues without affecting cardiac and skeletal systems.
2Productivity
If T3 is used to stimulate liver regeneration, then hepatomitogenic effects are improved, but toxic effects occur
Solution Approach 1:
The invention segments the receptor-mediated effects of thyroid hormones by selectively targeting TRβ for hepatomitogenic activity. This selective modulation enables liver regeneration stimulation while avoiding the toxic effects that result from non-selective TR activation by T3.
3Object-affected harmful factors
If selective TRβ modulators are developed, then cardiac side effects are avoided, but no effective drug currently exists for liver and neurodegenerative diseases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of thyroid hormone analogs to achieve selective TRβ binding. By altering molecular parameters (substituents on the phenolic ring, ether linkage position, carboxylic acid group), the invention creates compounds with optimized selectivity profiles that enable TRβ-specific modulation without TRα activation.
Data Source
AI summary
The invention concerns a compound of Formula (I) or a salt thereof, wherein R1 is H, (C1-C3)alkyl or CF3; R2 is H, (C1-C3)alkyl or CF3; A is CH2COOH, XCH2COOCH2CH3, XCH2COOH, XCH2CH2NH2, where X is nitrogen or oxygen atom; Ar is an aromatic fragment selected from the group consisting of (Ar1), (Ar2) and (Ar3); where R3 is H, —CH3, —CH2CH3 or CH3CO—, R4 is H or —CH3, R5 is H or —CH3, and R6 is H or —CH3. The compounds of Formula (I) can be used in the treatment of diseases modulated by thyroid hormone receptor-beta (TRb or TRβ).